Evidence map›Paper›PMID 42756059›Full record

ArticleFrontiers in immunology2026

An mRNA-based FimH nanoparticle vaccine against uropathogenic

Sandro Roier, Jessica M Devant, Michael E Hibbing, Annette Möbes, Carolin Kruth, Kristina Kovacikova, Steven M Martin, Chanpheng Phommaly, Thomas J Hannan, Edith Jasny

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sandro RoierCureVac SE, Tübingen, Germany.
Jessica M DevantCureVac SE, Tübingen, Germany.
Michael E HibbingFimbrion Therapeutics Inc., Saint Louis, MO, United States.
Annette MöbesCureVac SE, Tübingen, Germany.
Carolin KruthCureVac SE, Tübingen, Germany.
Kristina KovacikovaCureVac SE, Tübingen, Germany.
Steven M MartinFimbrion Therapeutics Inc., Saint Louis, MO, United States.
Chanpheng PhommalyFimbrion Therapeutics Inc., Saint Louis, MO, United States.
Thomas J HannanFimbrion Therapeutics Inc., Saint Louis, MO, United States.
Edith JasnyCureVac SE, Tübingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Increasing antimicrobial resistance and the high health and economic burden of frequent, recurring urinary tract infections (rUTIs) drive the need for an efficacious UTI vaccine. Most UTIs are caused by uropathogenic Methods: FimH Results: Conclusion: These preclinical data in rodents establish the FimH

Indexed as

Adhesins, Escherichia coliEscherichia coli InfectionsEscherichia coli VaccinesFimbriae ProteinsRNA, MessengerUrinary Tract InfectionsUropathogenic Escherichia coliAnimalsAntibodies, BacterialDisease Models, AnimalFemaleHeLa CellsHumansMiceMice, Inbred BALB CNanoparticlesAdhesins, Escherichia coliAntibodies, BacterialEscherichia coli VaccinesFimbriae ProteinsfimH protein, E coliNanovaccinesRNA, MessengerfimHmRNA vaccinenanoparticleUPECUPEC vaccineurinary tract infection (UTI)uropathogenic E. coli (UPEC)

Identifiers

PMID42756059
PMCPMC13582291

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.